ADVANCE 01 • Cardiometabolic
SGLT2 inhibitors beyond diabetes
What is new?
Cardiorenal therapy has expanded from glucose lowering to heart-failure and chronic-kidney-disease protection, including many patients without diabetes.Mechanism / concept
Proximal tubular SGLT2 blockade produces natriuresis and glycosuria, lowers intraglomerular pressure through tubuloglomerular feedback, and favorably alters congestion and renal workload.Where it fits clinically
Heart failure across the EF spectrum; CKD with appropriate eGFR/albuminuria profiles; type 2 diabetes with cardiorenal risk.Key evidence and why it matters
Large outcome programmes consistently show fewer heart-failure events and slower CKD progression; benefits appear early and are only partly explained by HbA1c reduction.Practical physician perspective
Think of the class as disease-modifying cardiorenal therapy. Check renal function/volume status and temporarily withhold during major acute illness or prolonged fasting when ketoacidosis risk rises.Limitations, adverse effects & cautions
Genital mycotic infection, volume depletion and rare euglycaemic ketoacidosis; glycaemic efficacy falls at low eGFR even when organ-protection may remain relevant.Take-home: Newer medicine should change practice only when the specific drug, device or diagnostic is supported for the patient’s indication. Always verify current approval, guideline position, dose, contraindications and local availability before clinical use.
Educational update module: “Newer” is time-sensitive. Regulatory approvals and guideline positions differ by country and can change. Content is for professional learning and must not replace current prescribing information, local protocols or specialist assessment.